Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mullen, Saul
NCT04714996: Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy	Recruiting	2a	24	RoW	ES-481, Placebo, Open-Label Extension Study	ES Therapeutics Australia Pty Ltd	Drug Resistant Epilepsy	12/23	12/23
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures	Completed	2	154	Europe, US, RoW	CVL-865, Placebo	Cerevel Therapeutics, LLC	Seizures	05/24	05/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mullen, Saul
NCT04714996: Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy	Recruiting	2a	24	RoW	ES-481, Placebo, Open-Label Extension Study	ES Therapeutics Australia Pty Ltd	Drug Resistant Epilepsy	12/23	12/23
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures	Completed	2	154	Europe, US, RoW	CVL-865, Placebo	Cerevel Therapeutics, LLC	Seizures	05/24	05/24